Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + toripalimab + pemetrexed + carboplatin + cisplatin
- Development stage
- Preclinical
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of surufatinib (a multi-target tyrosine kinase inhibitor), toripalimab (a PD-1 inhibitor), pemetrexed (a multitargeted antifolate cytotoxic agent), and two platinum-based chemotherapy drugs (carboplatin and cisplatin). Pemetrexed inhibits multiple enzymes in the folate pathway, interfering with both DNA and RNA synthesis. Carboplatin and cisplatin are platinum compounds that destroy quickly dividing cells. This specific five-drug combination is not well documented in the literature.
02
Targets
TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DHFR (Dihydrofolate reductase)CSF1R (Macrophage colony-stimulating factor receptor)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on surufatinib + toripalimab + pemetrexed + carboplatin + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + toripalimab + pemetrexed + carboplatin + cisplatin.